In breast cancer, the glycans recognized by MAL-I, ECA, NPA, BPL, BS-I, PTL-II, DBA, PNA, PHA-E + L, UEA-I, and PWM showed differential expression.41 In gastric cancer, the glycans recognized by ECA, PSA, PHA-E + L, HHL, PNA, EEL, MPL, and GSL-I showed differential expression.31 In hepatic carcinoma, the glycans recognized by MAL-II, SNA, WFA, PNA, and AAL showed differential expression.42 In lung cancer, the alteration in the glycopattern is different from breast cancer, gastric cancer and hepatic carcinoma. This evidence concerns the gene RPS19 and lung carcinoma.